Enrollment is underway in the Phase 2 stage of 4D Molecular Therapeutics’ AEROW trial with 2.5E14 vg set as the anticipated pivotal and commercial dose for 4D-710. The Cystic Fibrosis Foundation will provide up to $11 million in additional equity funding, including $7.5 million closed in October, bringing its total commitment to the company’s CF programs to nearly $32 million. A Phase 1 redosing cohort is planned to deliver a second 2.5E14 vg dose at least one year after the initial administration. Interim Phase 1 data are expected by year-end, focusing on n=9 patients treated at lower doses with functional endpoints including LCI2.5, ppFEV1, CFQ-R respiratory domain, HRCT-based structural changes, and paired lung biopsy readouts of transgene expression at 1–2 months and at 1–3 years.
The core development is a two-pronged acceleration: new capital tied to clinical milestones and the formation of a joint steering committee with CF Foundation to guide late-stage strategy, regulatory interactions, and operational execution. The package supports Phase 2 advancement, the redosing study, and Phase 3 readiness for 4D-710, an aerosolized AAV gene therapy designed for airway-wide CFTR expression with the potential for repeat dosing. Following review with the Foundation’s safety team and trial leadership, the program converged on 2.5E14 vg as the dose it intends to carry forward commercially.
Strategically, the move signals a push to validate a variant-agnostic, durable approach in a post-modulator era where many patients are clinically improved but still face pulmonary morbidity. The central risk in CF gene therapy has not been initial transduction but the ability to sustain benefit and overcome immunity to enable retreatment. Building a formal redosing cohort into Phase 1/2 and selecting a commercial dose early is an attempt to compress timelines and answer the gating questions that often stall AAV respiratory programs. The protocol’s emphasis on LCI2.5 and HRCT alongside ppFEV1 reflects a bid to capture earlier and structural signals in a population where large FEV1 shifts may be muted by background therapy, though regulators will scrutinize endpoint relevance across age groups and disease severity.
For sites and CROs, AEROW’s operational footprint is specialized. Aerosolized AAV administration requires facility readiness, device standardization, and biosafety procedures that differ from infusion or intrathecal workflows. The added multiple-breath washout requirements demand calibrated equipment, trained technicians, and rigorous quality control; centralized HRCT reads introduce imaging logistics and data throughput considerations. The redosing plan extends patient retention horizons and adds immunomonitoring and potential repeat biopsy scheduling, while background modulators complicate eligibility and endpoint variability. Vendors supporting pulmonary function lab standardization, imaging analytics, and long-term follow-up are likely to see increased engagement.
The near-term catalysts are clear: durability beyond 12 months, concordance between functional, structural, and patient-reported outcomes, and evidence that a second dose both restores expression and maintains an acceptable safety profile. Confirmation that 2.5E14 vg is exposure- and effect-adequate would lock the Phase 3 design, but execution hinges on manufacturing at inhalation scale, consistent lung deposition across sites, and management of neutralizing antibody dynamics after the first dose. If the redosing cohort generates convincing biological and clinical activity, the regulatory conversation could tilt toward an expedited path for patients who remain underserved by modulators. Watch enrollment velocity in a stabilized CF population, site footprint expansion capable of MBW and HRCT at scale, and whether the joint steering structure translates into earlier, aligned endpoint guidance across regions as the program approaches Phase 3.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
